These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 19536529)
1. Pitfalls in patient self-management of subcutaneous drug application: removal of rubber protection caps from ready-to-use syringes. Mengiardi S; Goepfert B; Tsakiris DA; Hersberger KE Eur J Clin Pharmacol; 2009 Oct; 65(10):1061-2. PubMed ID: 19536529 [No Abstract] [Full Text] [Related]
2. High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report. Rydzewska-Rosolowska A; Borawski J; Mysliwiec M Adv Med Sci; 2009; 54(2):199-202. PubMed ID: 19758969 [TBL] [Abstract][Full Text] [Related]
3. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory. Marmur JD; Lakhani M; El Rouby S; Cavusoglu E J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674 [TBL] [Abstract][Full Text] [Related]
4. [Clexane (enoxaparin) or Fragmin (dalteparin) as thrombolytics in hip surgery? Is Fragmin better than Clexane?]. Abildgaard U; Sandset PM Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2351; author reply 2352. PubMed ID: 8804214 [No Abstract] [Full Text] [Related]
5. [Clexane (enoxaparin) or Fragmin (dalteparin) as thrombolytics in hip surgery? Misunderstandings of the purchasing order in the municipality of Oslo]. Brørs O Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2351-2. PubMed ID: 8804215 [No Abstract] [Full Text] [Related]
6. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. Bajkin BV; Popovic SL; Selakovic SD J Oral Maxillofac Surg; 2009 May; 67(5):990-5. PubMed ID: 19375008 [TBL] [Abstract][Full Text] [Related]
7. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229 [TBL] [Abstract][Full Text] [Related]
9. Dosing and timing of low-molecular-weight heparin thromboprophylaxis in total hip arthroplasty. Colwell CW Orthopedics; 2003 Nov; 26(11):1155-61; quiz 1162-3. PubMed ID: 14627117 [No Abstract] [Full Text] [Related]
10. In vitro anticoagulation monitoring of low-molecular-weight heparin. Wang JQ; Shi XB; Yang JG; Hu DY Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471 [TBL] [Abstract][Full Text] [Related]
11. Acute generalized exanthematous pustulosis from dalteparin. Komericki P; Grims R; Kränke B; Aberer W J Am Acad Dermatol; 2007 Oct; 57(4):718-21. PubMed ID: 17610994 [TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin as an adjunct to thrombolysis in ST elevation myocardial infarction. Quinlan DJ; Eikelboom JW Arch Intern Med; 2009 Jun; 169(12):1163-4. PubMed ID: 19546418 [No Abstract] [Full Text] [Related]
14. Which DVT patients could be considered the best candidates for home therapy? Monreal M Thromb Haemost; 1999 Jun; 81(6):996-7. PubMed ID: 10404787 [No Abstract] [Full Text] [Related]
15. A case series of five episodes of massive LMWH non-fatal self-induced overdose in a single patient. Odeberg J; Carlsson A; Hällsjö-Sander C; Agren A Thromb Res; 2012 May; 129(5):668-70. PubMed ID: 22261479 [No Abstract] [Full Text] [Related]
16. Adjusting the dose of low molecular weight heparins in renally impaired and obese patients. Spinler S Clin Adv Hematol Oncol; 2004 May; 2(5):270, 273-4. PubMed ID: 16163192 [No Abstract] [Full Text] [Related]
17. [Thrombolysis in pulmonary embolism with unstable hemodynamics can be life-saving. Discussed treatment strategy--two cases illustrate the problem]. Söderberg M; Edsberg J Lakartidningen; 2008 Oct 29-Nov 4; 105(44):3112-4. PubMed ID: 19031977 [No Abstract] [Full Text] [Related]
18. [Subcutaneous catheter used for administration of low-molecular-weight-heparin in pediatrics]. Márquez N R; Pino A P; Zúñiga C P Rev Chil Pediatr; 2014 Feb; 85(1):46-51. PubMed ID: 25079183 [TBL] [Abstract][Full Text] [Related]
19. [Ambulatory therapy of thrombosis with low molecular weight heparin. Further simplification by one-time administration]. MMW Fortschr Med; 2001 Mar; 143(13):52-3. PubMed ID: 11332024 [No Abstract] [Full Text] [Related]
20. Successful heparin desensitization after anaphylactic shock due to heparin. Altintaş ND; Aybar Türkoğlu M; Bozkurt B; Topeli Iskit A; Karakaya G; Kalyoncu AF Tuberk Toraks; 2009; 57(1):68-72. PubMed ID: 19533440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]